This document is an excerpt from the EUR-Lex website
Document 52019M9315
Prior notification of a concentration (Case M.9315 — Chr. Hansen/Lonza/JV) (Text with EEA relevance.)
Prior notification of a concentration (Case M.9315 — Chr. Hansen/Lonza/JV) (Text with EEA relevance.)
Prior notification of a concentration (Case M.9315 — Chr. Hansen/Lonza/JV) (Text with EEA relevance.)
OJ C 208, 19.6.2019, pp. 6–7
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
19.6.2019 |
EN |
Official Journal of the European Union |
C 208/6 |
Prior notification of a concentration
(Case M.9315 — Chr. Hansen/Lonza/JV)
(Text with EEA relevance)
(2019/C 208/05)
1.
On 11 June 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Chr. Hansen Holding A/S (‘Chr. Hansen’, Denmark), |
|
— |
Lonza Ltd (‘Lonza’, Switzerland), controlled by Lonza Group Ltd, |
|
— |
A newly created joint venture (the ‘JV’, Switzerland). |
Chr. Hansen and Lonza acquire, within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation, joint control over the JV.
The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.
2.
The business activities of the undertakings concerned are:— for Chr. Hansen: the development of natural solutions for the food, nutritional, pharmaceutical and agricultural industries,
— for Lonza: the provision of various services from research to final product manufacturing in the pharmaceutical, healthcare and life science industries, including contract development and manufacturing services (‘CDMO’) and services related to drug formulation services and drug delivery technologies,
— for the JV: the supply of CDMO services to pharmaceutical companies in relation to live biotherapeutic products and phages.
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9315 — Chr. Hansen/Lonza/JV
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
|
Email: COMP-MERGER-REGISTRY@ec.europa.eu |
|
Fax +32 22964301 |
|
Postal address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).